Citi Upgrades Bellicum Pharmaceuticals (BLCM) to Buy
- Wall Street gains, helped by oil, economic data
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- Unusual 11 Mid-Day Movers 12/5: (NVCN) (BCEI) (MEMP) Higher; (GTXI) (CERC) (HDSN) Lower
- Oil hits 16-month high in buying rush after OPEC agreement
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Citi upgraded Bellicum Pharmaceuticals (NASDAQ: BLCM) from Neutral to Buy with a price target of $24.00.
Shares of Bellicum Pharmaceuticals closed at $17.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bellicum Pharma (BLCM) Luncheon Today May Offer Insight Into Expedited Approval For Non-Malig Immunodeficiency Therapy - Jefferies
- Instinet Upgrades McDonald's (MCD) to Buy
- UPDATE: Stifel Upgrades TripAdvisor (TRIP) to Hold